Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...
The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
16hon MSN
To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...
Apollo Global Management, Novo Nordisk A/S, BlackRock, Blackstone, and Prologis are the five Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of ...
Vivani Medical, Inc. (NASDAQ:VANI) announced the administration of its first GLP-1 (exenatide, NPM-115) implant in the ...
Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...
After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results